Protagonist Therapeutics price to book ratio PTGX

Market value divided by the book value of the company's net assets, since 2016.

Today, Oct 23, 2026: 10.6×
10-year median: 4.2×
Against its 10-year history: 96th; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.1× to 13.8×
Peer median: 9.2×

Protagonist Therapeutics' price to book ratio is 10.6× as of Oct 23, 2026.

That is above its ten-year median of 4.2×, higher than on 96% of days in the last ten years.

Over that time it ranged from 1.1× in May 2018 to 13.8× in Jul 2026.

The median for 10 large drugmakers of a similar size is 9.2×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	10.6×	7.8×	13.8×
2025	8.6×	3.4×	9.2×
2024	4.4×	2.9×	5.6×
2023	4.4×	2.4×	7.7×
2022	2.2×	1.2×	5.2×
2021	5.0×	2.3×	8.4×
2020	4.5×	1.9×	8.1×
2019	2.0×	1.4×	4.8×
2018	1.2×	1.1×	7.6×
2017	7.4×	1.8×	7.4×
2016	3.8×	3.8×	4.4×

Against its peers

Companies in Drug Manufacturers - General nearest Protagonist Therapeutics' size, closest first, today.

Company	Price to book ratio
PTGXProtagonist Therapeutics	10.6×
CORTCorcept Therapeutics	13.2×
TGTXTG Therapeutics	13.7×
BMRNBiomarin Pharmaceutical	1.7×
ALKSAlkermes plc.	4.0×
AMRXAmneal Pharmaceuticals	197×
LGNDLigand Pharmaceuticals	6.3×
KNSAKiniksa Pharmaceuticals International	9.2×
JAZZJazz Pharmaceuticals	2.9×
INDVIndivior Pharmaceuticals	n/m
ARQTArcutis Biotherapeutics	17.8×
Peer median	9.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Protagonist Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.